We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medifast (MED) Q3 Earnings: Coaches & OPTAVIA are Key Drivers
Read MoreHide Full Article
Medifast, Inc (MED - Free Report) is scheduled to release third-quarter 2018 results on Nov 6, after market close. Earnings of this renowned weight management and nutritional products company beat the Zacks Consensus Estimate in the past 10 quarters. Moreover, revenues surpassed estimates in the trailing four quarters. The company’s top- and bottom-line performances have been impressive on a year-over-year basis.
Let’s see how things are shaping up prior to the upcoming quarterly announcement and discuss if the company can sustain robust performance trend.
Sturdy Increase in Coaches: A Key Catalyst
Medifast relies on earning coaches for revenue generation. Coaches not only form a vital sales channel, but also act as advisors to clients and help reach out to new customers by generating awareness regarding products and health programs. Notably, the company is steadily gaining from growth in active earning coaches base. In fact, during the second quarter of 2018, active earnings coaches increased almost 46% to 19,700. Also, in the said period, average revenues generated by these coaches increased 16.1% to reach $5,474. This substantially aided top-line growth. Moreover, the company is on track with training and development of coaches to continue enhancing their productivity.
Growth in OPTAVIA Likely to Sustain
Medifast has been steadily gaining from the OPTAVIA brand for a while. The brand represented almost 64% and 58% of the company’s consumable unit sales during the second and the first quarters of 2018, respectively. The brand is supported by approximately 71 SKUs, which aids the company’s coaches to reach out to clients effectively and boost revenues. Further, the company engages in holding conventions, specifically focusing on the OPTAVIA brand that helps training new coaches and discussing strategies for sustaining growth. Such endeavors are likely to continue aiding advancement of the OPTAVIA brand and fuel the company’s top-line performance.
Consumers’ growing inclination toward health and fitness encourages Medifast to continue investing toward growth of its brands and tap into the rising demand for healthy products. In this respect, management is on track with strengthening the e-commerce platform through technological upgradations. Further, the company is on track with augmenting distribution base. In fact, a new distribution center was opened during the second quarter in Nevada. Apart from these, Medifast is also on track with expanding business internationally, especially in the Asian markets.
Estimates Unveil Bright Prospects
We expect the aforementioned factors to continue aiding Medifast’s performance in the upcoming quarterly release. In fact, such endeavors are anticipated to help the company in cushioning the hurdles related to rising expenses, stemming primarily from growing client base and higher discounts.
Incidentally, Management expects revenues for the third quarter in the range of $120-$125 million, depicting growth from $77 million in the prior-year quarter. The Zacks Consensus Estimate for revenues for the third quarter is currently pegged at $125 million.
Additionally, the Zacks Consensus Estimate for earnings for the impending quarter is currently pegged at $1.15, reflecting an improvement from 55 cents reported in the year-ago quarter. This estimate has been stable in the past 30 days. Further, management predicts earnings for the quarter under review in the range of $1.05-$1.10.
What Does the Zacks Model Predict?
Our proven model doesn’t show that Medifast can beat bottom-line estimates this quarter. For this to happen, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are a few companies you may want to consider as our model shows that they have the right combination of elements to post an earnings beat:
The Hain Celestial Group, Inc (HAIN - Free Report) has an Earnings ESP of +5.66% and a Zacks Rank #3.
Nu Skin Enterprises, Inc (NUS - Free Report) has an Earnings ESP of +0.21% and a Zacks Rank #3.
Turning Point Brands, Inc (TPB - Free Report) has an Earnings ESP of +8.74% and a Zacks Rank #3.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
Medifast (MED) Q3 Earnings: Coaches & OPTAVIA are Key Drivers
Medifast, Inc (MED - Free Report) is scheduled to release third-quarter 2018 results on Nov 6, after market close. Earnings of this renowned weight management and nutritional products company beat the Zacks Consensus Estimate in the past 10 quarters. Moreover, revenues surpassed estimates in the trailing four quarters. The company’s top- and bottom-line performances have been impressive on a year-over-year basis.
Let’s see how things are shaping up prior to the upcoming quarterly announcement and discuss if the company can sustain robust performance trend.
Sturdy Increase in Coaches: A Key Catalyst
Medifast relies on earning coaches for revenue generation. Coaches not only form a vital sales channel, but also act as advisors to clients and help reach out to new customers by generating awareness regarding products and health programs. Notably, the company is steadily gaining from growth in active earning coaches base. In fact, during the second quarter of 2018, active earnings coaches increased almost 46% to 19,700. Also, in the said period, average revenues generated by these coaches increased 16.1% to reach $5,474. This substantially aided top-line growth. Moreover, the company is on track with training and development of coaches to continue enhancing their productivity.
Growth in OPTAVIA Likely to Sustain
Medifast has been steadily gaining from the OPTAVIA brand for a while. The brand represented almost 64% and 58% of the company’s consumable unit sales during the second and the first quarters of 2018, respectively. The brand is supported by approximately 71 SKUs, which aids the company’s coaches to reach out to clients effectively and boost revenues. Further, the company engages in holding conventions, specifically focusing on the OPTAVIA brand that helps training new coaches and discussing strategies for sustaining growth. Such endeavors are likely to continue aiding advancement of the OPTAVIA brand and fuel the company’s top-line performance.
MEDIFAST INC Price, Consensus and EPS Surprise
MEDIFAST INC Price, Consensus and EPS Surprise | MEDIFAST INC Quote
Other Strategic Efforts
Consumers’ growing inclination toward health and fitness encourages Medifast to continue investing toward growth of its brands and tap into the rising demand for healthy products. In this respect, management is on track with strengthening the e-commerce platform through technological upgradations. Further, the company is on track with augmenting distribution base. In fact, a new distribution center was opened during the second quarter in Nevada. Apart from these, Medifast is also on track with expanding business internationally, especially in the Asian markets.
Estimates Unveil Bright Prospects
We expect the aforementioned factors to continue aiding Medifast’s performance in the upcoming quarterly release. In fact, such endeavors are anticipated to help the company in cushioning the hurdles related to rising expenses, stemming primarily from growing client base and higher discounts.
Incidentally, Management expects revenues for the third quarter in the range of $120-$125 million, depicting growth from $77 million in the prior-year quarter. The Zacks Consensus Estimate for revenues for the third quarter is currently pegged at $125 million.
Additionally, the Zacks Consensus Estimate for earnings for the impending quarter is currently pegged at $1.15, reflecting an improvement from 55 cents reported in the year-ago quarter. This estimate has been stable in the past 30 days. Further, management predicts earnings for the quarter under review in the range of $1.05-$1.10.
What Does the Zacks Model Predict?
Our proven model doesn’t show that Medifast can beat bottom-line estimates this quarter. For this to happen, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Although Medifast currently carries a Zacks Rank #3, its Earnings ESP of 0.00% reduces chances of an earnings beat. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks Poised to Beat Earnings Estimates
Here are a few companies you may want to consider as our model shows that they have the right combination of elements to post an earnings beat:
The Hain Celestial Group, Inc (HAIN - Free Report) has an Earnings ESP of +5.66% and a Zacks Rank #3.
Nu Skin Enterprises, Inc (NUS - Free Report) has an Earnings ESP of +0.21% and a Zacks Rank #3.
Turning Point Brands, Inc (TPB - Free Report) has an Earnings ESP of +8.74% and a Zacks Rank #3.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>